BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Integrates Radiation Dose Personalization into IzoView Breast CT System

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company focused on advanced breast cancer imaging technologies, announced the integration of a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System. The innovation uses a radiation-free optical pre-scan and proprietary software to calculate customized dosing for each patient’s breast size, streamlining exam setup and improving comfort. Developed using models from UC Davis Medical Center, the system positions IzoView as the first breast CT to offer real-time personalized dosing. With the global breast imaging market projected to grow to $8.69 billion by 2030, Izotropic is advancing IzoView through the FDA Pre-Market Approval process and preparing pivotal U.S. trials to support commercialization in both U.S. and European markets.

To view the full press release, visit https://ibn.fm/HSe0t

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN